Quantum BioPharma Valuation
| QNTM Stock | 3.85 0.10 2.53% |
At this time, the company appears to be overvalued. Quantum BioPharma holds a recent Real Value of USD3.79 per share. The prevailing price of the company is USD3.85. Our model determines the value of Quantum BioPharma from analyzing the company fundamentals such as Return On Equity of -2.51, price to book of 1.84 X, and Shares Outstanding of 3.84 M as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Quantum BioPharma's valuation include:
Price Book 1.8389 | Enterprise Value | Enterprise Value Ebitda (1.57) | Price Sales 91.8563 | Enterprise Value Revenue 98.5599 |
Overvalued
Today
Please note that Quantum BioPharma's price fluctuation is dangerous at this time. Calculation of the real value of Quantum BioPharma is based on 3 months time horizon. Increasing Quantum BioPharma's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Quantum stock is determined by what a typical buyer is willing to pay for full or partial control of Quantum BioPharma. Since Quantum BioPharma is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Quantum Stock. However, Quantum BioPharma's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 3.85 | Real 3.79 | Hype 3.88 |
The intrinsic value of Quantum BioPharma's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Quantum BioPharma's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Quantum BioPharma helps investors to forecast how Quantum stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Quantum BioPharma more accurately as focusing exclusively on Quantum BioPharma's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Quantum BioPharma's intrinsic value based on its ongoing forecasts of Quantum BioPharma's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Quantum BioPharma's closest peers.
Quantum BioPharma Cash |
|
Quantum Valuation Drivers Correlation
Many accounts on the financial statements of Quantum BioPharma are highly interrelated and sometimes correlated. Consequently, when conducting Quantum's valuation analysis, one should examine all of the accounts reported to obtain a complete picture of its financial situation. We provide a unique feature to present a conventional correlation table purposely composed against different valuation-related drivers of Quantum
Click cells to compare fundamentals
Quantum BioPharma Total Value Analysis
Quantum BioPharma is at this time anticipated to have valuation of 17.45 M with market capitalization of 15.14 M, debt of 824.92 K, and cash on hands of . Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Quantum BioPharma fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
17.45 M | 15.14 M | 824.92 K |
Quantum BioPharma Asset Utilization
One of the ways to look at asset utilization of Quantum is to check how much profit was generated for every dollar of assets it reports. Quantum BioPharma holds a negative application of assets of -0.72 pct., losing USD0.007222 for each dollar of assets held by the company. Inadequate asset utilization implies the company is being less effective with each dollar of assets it holds. Put it differently, asset utilization of Quantum BioPharma shows how discouraging it operates for each dollar spent on its assets.Quantum BioPharma Profitability Analysis
Based on the key profitability measurements obtained from Quantum BioPharma's financial statements, Quantum BioPharma may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in March. Profitability indicators assess Quantum BioPharma's ability to earn profits and add value for shareholders.Net Loss | First Reported 2016-03-31 | Previous Quarter -9.3 M | Current Value -5.3 M | Quarterly Volatility 4.8 M |
For Quantum BioPharma profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Quantum BioPharma to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Quantum BioPharma utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Quantum BioPharma's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Quantum BioPharma over time as well as its relative position and ranking within its peers.
Quantum BioPharma Earnings per Share Projection vs Actual
The next projected EPS of Quantum BioPharma is estimated to be -1.28875 with future projections ranging from a low of -1.28875 to a high of -1.28875. Quantum BioPharma's most recent 12-month trailing earnings per share (EPS TTM) is at -9.55. Please be aware that the consensus of earnings estimates for Quantum BioPharma is based on EPS before non-recurring items and includes expenses related to employee stock options.Quantum BioPharma Earnings Estimation Breakdown
The calculation of Quantum BioPharma's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Quantum BioPharma is estimated to be -1.28875 with the future projection ranging from a low of -1.28875 to a high of -1.28875. Please be aware that this consensus of annual earnings estimates for Quantum BioPharma is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-1.29 Lowest | Expected EPS | -1.29 Highest |
Quantum BioPharma Earnings Projection Consensus
Suppose the current estimates of Quantum BioPharma's value are higher than the current market price of the Quantum BioPharma stock. In this case, investors may conclude that Quantum BioPharma is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Quantum BioPharma's stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2026 | Current EPS (TTM) | |
| 1 | 80.56% | -2.7 | -1.28875 | -9.55 |
Quantum BioPharma Ownership Allocation
The market capitalization of Quantum BioPharma is USD15.14 Million. Quantum BioPharma holds 8.64 pct. of its outstanding shares held by insiders and 11.43 pct. owned by third-party entities. Note, that even with negative profits, if the true value of the company is larger than the current market value, you may still be able to generate positive returns on investment in this company.Quantum BioPharma Profitability Analysis
Net Loss for the year was (14.92 M) with profit before overhead, payroll, taxes, and interest of 0.About Quantum BioPharma Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Quantum BioPharma. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Quantum BioPharma based exclusively on its fundamental and basic technical indicators. By analyzing Quantum BioPharma's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Quantum BioPharma's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Quantum BioPharma. We calculate exposure to Quantum BioPharma's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Quantum BioPharma's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -441.5 K | -463.6 K | |
| Pretax Profit Margin | (122.27) | (128.39) | |
| Operating Profit Margin | (122.27) | (128.39) | |
| Net Loss | (122.27) | (128.39) |
Quantum BioPharma Current Valuation Indicators
Quantum BioPharma's valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Quantum BioPharma's valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Quantum BioPharma, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Quantum BioPharma's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Quantum BioPharma's worth.When determining whether Quantum BioPharma is a strong investment it is important to analyze Quantum BioPharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Quantum BioPharma's future performance. For an informed investment choice regarding Quantum Stock, refer to the following important reports: Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Quantum BioPharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. To learn how to invest in Quantum Stock, please use our How to Invest in Quantum BioPharma guide.You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.
Will Biotechnology sector continue expanding? Could Quantum diversify its offerings? Factors like these will boost the valuation of Quantum BioPharma. Anticipated expansion of Quantum directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Quantum BioPharma data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
The market value of Quantum BioPharma is measured differently than its book value, which is the value of Quantum that is recorded on the company's balance sheet. Investors also form their own opinion of Quantum BioPharma's value that differs from its market value or its book value, called intrinsic value, which is Quantum BioPharma's true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Quantum BioPharma's market value can be influenced by many factors that don't directly affect Quantum BioPharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Quantum BioPharma's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Quantum BioPharma should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Quantum BioPharma's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.